蕈样肉芽肿与Sézary综合征的血源性播散:当前证据与临床意义
本文综述支持蕈样肉芽肿(MF)与Sézary综合征(SS)血源性播散假说的证据,提出恶性转化可能发生于T细胞发育早期,循环肿瘤细胞定植皮肤并连续再播散,推动疾病进展。该模型将MF/SS从原发皮肤疾病转变为系统性疾病的认知,对血液肿瘤负荷评估、预后监测及联合治疗研究具有临床意义。
要点
- MF/SS可能起源于T细胞发育早期的恶性转化,循环肿瘤细胞定植皮肤后增殖演化。
- 连续血源性播散假说可解释远隔部位皮损及同步转录组趋同现象。
- 该模型提示血液肿瘤负荷评估、预后监测与联合治疗策略需重新审视。
核心结论
- 血源性播散可能是MF/SS发病与进展的关键过程,而非仅见于晚期。
- 该模型将MF/SS从原发皮肤疾病转变为系统性疾病认知。
研究设计与样本
- 本文为叙述性综述,检索并汇总支持MF/SS血源性播散假说的证据。
主要发现
- 远隔部位皮损提示MF/SS病灶可能通过血源性播散发生。
- 恶性T细胞可重入血流、再播散至原有及新发皮肤区域,引起皮损转录组同步趋同变化。
- 成熟T细胞前体模型并不总与临床观察和MF/SS发病研究一致。
临床怎么用
- 重新审视血液肿瘤负荷的标准化评估方法。
- 探索预后与疾病监测的潜在改进方向。
- 研究联合治疗以改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of diseases characterized by abnormal neoplastic T-cell growth in the skin. Mycosis fungoides (MF), the most common CTCL, manifests as erythematous skin patches and/or plaques, tumours or erythroderma. The disease may involve blood, lymph nodes and rarely viscera. Sézary syndrome (SS) is a unique leukaemia/lymphoma syndrome related to MF, which presents with blood and skin involvement at diagnosis. The pathogenesis of MF/SS is not fully elucidated. The presence of skin lesions at distant sites underpins a hypothesis that MF/SS lesions may develop through haematogenous seeding. Phenotypic similarities between malignant and normal T cells led to the notion that disease-initiating mutations occur in specific subtypes of mature T cells, which are responsible for most CTCLs. However, this mature T-cell precursor model is not always consistent with clinical observations and research on MF/SS pathogenesis. Here, we review evidence supporting an alternative model of pathogenesis for MF/SS involving haematogenous seeding as a key process responsible for the initiation and progression of the disease. According to this hypothesis, malignant transformation occurs at an early stage of T-cell development (probably in bone marrow or thymus), yielding circulating neoplastic T cells which colonize the skin where the microenvironment is most permissive for proliferation and evolution. These mutated precursor cells seed the skin where they find a suitable niche to develop into clinically perceptible disease. Subsequently, malignant T cells can re-enter the bloodstream, re-seed pre-existing lesions and seed new areas of the skin, causing synchronous and convergent changes in the transcriptomic profile of lesions and tumours, and clinical disease progression - 'consecutive haematogenous seeding' captures this temporal phenomenon. This model radically changes the current understanding of CTCL pathogenesis, transforming it from a primarily cutaneous disease with secondary involvement of blood, to a systemic disease, where the spread of malignant cells through the blood to the skin is not a phenomenon of advanced disease but is an essential component of pathogenesis. This understanding of MF/SS could have several clinical implications, including standardizing our approach to assessing blood tumour burden, potential advances in prognosis and monitoring, and investigating combination treatments to improve patient outcomes. Mycosis fungoides (or ‘MF’ for short) is a skin cancer caused by a type of immune cell called lymphocytes. People with MF develop patches, plaques and tumours on their skin. They can also develop widespread redness caused by the uncontrolled growth of lymphocytes. We thought that MF developed only from problems in lymphocytes in the skin. Recent research challenges this view and suggests that cells in the blood also play an important role in the development of MF. We introduce a new concept to explain MF. We suggest that cancer cells may develop in the immune system first, long before showing up in the skin. These cells can travel through the bloodstream and settle in the skin, where they grow more easily. Cancerous cells from skin lesions can also re-enter the bloodstream and move to new areas of the skin, spreading and worsening the disease. This research changes how we see MF. Rather than being a skin disease, it is a problem that affects the whole body. This could affect treatment by improving ways of detecting cancer cells in the blood, watching for disease changes and exploring treatments to help patients better.
引用
- Gniadecki R, Guenova E, Querfeld C, et al. Haematogenous seeding in mycosis fungoides and Sézary syndrome: current evidence and clinical implications. Br J Dermatol. 2025. PMID: 39545505. doi:10.1093/bjd/ljae441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。